Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: From diagnosis to prognosis

Gynecologic Oncology

Volumn 103, Issue 1, 2006, Pages 165-170

  Chung, Hyun Hoon ^a   Kim, Seok Ki ^a   Kim, Tae Hyun ^a   Lee, Sun ^a   Kang, Keon Wook ^a   Kim, Joo Young ^a   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cervical cancer; FDG PET; Recurrent; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PAPANICOLAOU TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; PELVIC EXENTERATION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 33748545361     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.02.016     Document Type: Article

References (42)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
2. Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P., et al. Carcinoma of the cervix uteri. J. Epidemiol. Biostat. 24 (2000) 7-43
3. Kato H., and Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40 (1977) 1621-1628
4. Chan Y.M., Ng T.Y., Ngan H.Y., and Wong L.C. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective?. Gynecol. Oncol. 84 (2002) 7-11
5. Esajas M.D., Duk J.M., de Bruijn H.W., Aalders J.G., Willemse P.H., Sluiter W., et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J. Clin. Oncol. 19 (2001) 3960-3966
6. Lozza L., Merola M., Fontanelli R., Stefanon B., Seregni E., Bombardieri E., et al. Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurements. Anticancer Res. 17 (1997) 525-529
7. Micke O., Prott F.J., Schafer U., Tangerding S., Potter R., and Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 20 (2000) 5113-5115
8. Bolli J.A., Doering D.L., Bosscher J.R., Day Jr. T.G., Rao C.V., Owens K., et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol. Oncol.. 55 (1994) 169-173
9. Chang T.C., Law K.S., Hong J.H., Lai C.H., Ng K.K., Hsueh S., et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer 101 1 (2004) 164-171
10. Chou H.H., Wang C.C., Lai C.H., Hong J.H., Ng K.K., Chang T.C., et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 442-448
11. Larson D.M., Copeland L.J., Stringer C.A., Gershenson D.M., Malone Jr. J.M., and Edwards C.L. Recurrent cervical carcinoma after radical hysterectomy. Gynecol. Oncol. 30 (1988) 381-387
12. Cave L. HCFA approves Medicare coverage of PET scans. J. Natl. Cancer Inst. 93 (2001) 177
13. Digby W., and Keppler J. The current status of positron emission tomography. Radiol. Manage. 22 (2000) 37-40
14. Strauss L.G., Clorius J.H., Schlag P., Lehner B., Kimmig B., Engenhart R., et al. Recurrence of colorectal tumors: PET evaluation. Radiology 170 (1989) 329-332
15. Delbeke D., Vitola J.V., Sandler M.P., Arildsen R.C., Powers T.A., and Wright Jr. J.K. Staging recurrent metastatic colorectal carcinoma with PET. J. Nucl. Med. 38 (1997) 1196-1201
16. Flamen P., Stroobants S., Van Cutsem E., Dupont P., Bormans G., De Vadder N., et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose in recurrent colorectal cancer. J. Clin. Oncol. 17 (1999) 894-901
17. Umesaki N., Tanaka T., Miyama M., Tokuyama O., Kawamura N., Ogita S., et al. Early diagnosis and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography. Oncol. Rep. 7 (2000) 53-56
18. Umesaki N., Tanaka T., Miyama M., Kawabe J., Okamura T., Koyama K., et al. The role of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer. Oncol. Rep. 7 (2000) 1261-1264
19. Unger J.B., Ivy J.J., Connor P., Charrier A., Ramaswamy M.R., Ampil F.L., et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol. Oncol. 94 1 (2004 (Jul.)) 212-216
20. Sun S.S., Chen T.C., Yen R.F., Shen Y.Y., Changlai S.P., and Kao A. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res. 21 (2001) 2957-2961
21. Grigsby P.W., Siegel B.A., Dehdashti F., and Mutch D.G. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 907-913
22. Havrilesky L.J., Wong T.Z., Secord A.A., Berchuck A., Clarke-Pearson D.L., and Jones E.L. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol. Oncol. 90 (2003) 186-190
23. von Schulthess G.K. Clinical PET and PET/CT imaging in body oncology. In: von Schulthess G.K. (Ed). Clinical Molecular Anatomic Imagings (2003), J.B.Lippincott Company, Philadelphia, PA 249
24. Kim S., Chung J.K., Kim B.T., Kim S.J., Jeong J.M., Lee D.S., et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin. Positron. Imaging 2 5 (1999) 273-279
25. Bodurka-Bevers D., Morris M., and Eifel P. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol. Oncol. 78 (2000) 187-193
26. Soisson A.P., Geszler G., and Soper J.T. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet. Gynecol. 76 (1990) 106-109
27. Yamashita Y., Harada M., Torashima M., Takahashi M., Miyazaki K., Tanaka N., et al. Dynamic MR imaging of recurrent postoperative cervical cancer. J. Magn. Reson. Imaging 6 (1996) 167-171
28. Belhocine T., Thille A., Fridman V., Albert A., Seidel L., Nickers P., et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol. Oncol. 87 (2002) 90-97
29. Ryu S.Y., Kim M.H., Choi S.C., Choi C.W., and Lee K.H. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J. Nucl. Med. 44 (2003) 347-352
30. Wagenaar H.C., Trimbos J.B., Postema S., Anastasopoulou A., van der Geest R.J., Reiber J.H., et al. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. Gynecol. Oncol. 82 (2001) 474-482
31. Hricak H., and Yu K.K. Radiology in invasive cervical cancer. Am. J. Roentgenol. 167 (1996) 1101-1108
32. Subak L.L., Hricak H., Powell C.B., Azizi L., and Stern J.L. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet. Gynecol. 86 (1995) 43-50
33. Kim S.H., Choi B.I., Han J.K., Kim H.D., Lee H.P., Kang S.B., et al. Preoperative staging of uterine cervical carcinoma: comparison of CT and MR imaging in 99 patients. J. Comput. Assist. Tomogr. 17 (1993) 633-640
34. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41 (2000) 661-681
35. Nakamoto Y., Eisbruch A., Achtyes E.D., Sugawara Y., Reynolds K.R., Johnston C.M., et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol. Oncol. 84 (2002) 289-295
36. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D., Ihling C., Hogerle S., Mix M., et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG-PET. Radiology 218 (2001) 776-782
37. Rose P.G., Adler L.P., Rodriguez M., Faulhaber P.F., Abdul-Karim F.W., and Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J. Clin. Oncol. 17 (1999) 41-45
38. Sugawara Y., Eisbruch A., Kosuda S., Recker B.E., Kison P.V., and Wahl R.L. Evaluation of FDG-PET in patients with cervical cancer. J. Nucl. Med. 40 (1999) 1125-1131
39. Williams A.D., Cousins C., Soutter W.P., Mubashar M., Peters A.M., Dina R., et al. Detection of pelvic lymph node metastases in gynecologic malignancy: a comparison of CT, MR imaging, and positron emission tomography. Am. J. Roentgenol. 177 (2001) 343-348
40. Abe A., Nakano T., Morita S., and Oka K. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer. Anticancer Res. 19 (1999) 829-836
41. Juang C.M., Wang P.H., Yen M.S., Lai C.R., Ng H.T., and Yuan C.C. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 76 (2000) 103-106
42. Suzuki Y., Nakano T., Ohno T., Abe A., Morita S., and Tsujii H. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. J. Cancer Res. Clin. Oncol. 126 (2000) 332-336